These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 36410041)

  • 21. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
    Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
    Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    You SC; Rho Y; Bikdeli B; Kim J; Siapos A; Weaver J; Londhe A; Cho J; Park J; Schuemie M; Suchard MA; Madigan D; Hripcsak G; Gupta A; Reich CG; Ryan PB; Park RW; Krumholz HM
    JAMA; 2020 Oct; 324(16):1640-1650. PubMed ID: 33107944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Net Clinical Benefit Between Clopidogrel and Ticagrelor Following Percutaneous Coronary Intervention in Patients in China With Acute Coronary Syndrome.
    Li D; Sun Y; Ye X; Li L; Chen Y; Wang D
    Adv Ther; 2022 Jan; 39(1):754-766. PubMed ID: 34904209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
    Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D
    Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
    Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
    Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
    Tomaniak M; Chichareon P; Onuma Y; Deliargyris EN; Takahashi K; Kogame N; Modolo R; Chang CC; Rademaker-Havinga T; Storey RF; Dangas GD; Bhatt DL; Angiolillo DJ; Hamm C; Valgimigli M; Windecker S; Steg PG; Vranckx P; Serruys PW;
    JAMA Cardiol; 2019 Nov; 4(11):1092-1101. PubMed ID: 31557763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials.
    Baber U; Jang Y; Oliva A; Cao D; Vogel B; Dangas G; Sartori S; Spirito A; Smith KF; Branca M; Collier T; Pocock S; Valgimigli M; Kim BK; Hong MK; Mehran R
    Circulation; 2024 Feb; 149(8):574-584. PubMed ID: 37870970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries.
    Peyracchia M; Saglietto A; Biolè C; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Wilton SB; Velicki L; Xanthopoulou I; Correia L; Rognoni A; Fabrizio U; Nuñez-Gil I; Montabone A; Taha S; Fujii T; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Kawaji T; Blanco PF; Garay A; Quadri G; Queija BC; Huczek Z; Paz RC; González-Juanatey JR; Fernández MC; Nie SP; D'Amico M; Pousa IM; Kawashiri MA; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Lopez-Cuenca A; Cequier A; Alexopoulos D; Iñiguez-Romo A; Grossomarra W; Usmiani T; Rinaldi M; D'Ascenzo F
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):259-269. PubMed ID: 31586336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machine-learning decision tree approaches.
    Xue Y; Hu Z; Jing Y; Wu H; Li X; Wang J; Seybert A; Xie X; Lv Q
    J Clin Pharm Ther; 2020 Oct; 45(5):1076-1086. PubMed ID: 32627223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
    Song PS; Park YH; Oh JH; Song YB; Choi SH; Gwon HC; Cho DK; Rha SW; Bae JW; Jeong JO; Hahn JY;
    Am J Cardiol; 2021 Jul; 150():47-54. PubMed ID: 34011436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial.
    Park DW; Kwon O; Jang JS; Yun SC; Park H; Kang DY; Ahn JM; Lee PH; Lee SW; Park SW; Choi SW; Lee SG; Yoon HJ; Ahn T; Kim MH; Nah DY; Lee SY; Chae JK; Park SJ;
    Circulation; 2019 Dec; 140(23):1865-1877. PubMed ID: 31553203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
    Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries.
    Bianco M; Careggio A; Biolè CA; Quadri G; Quiros A; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solè A; Liebetrau C; Manzano-Fernàndez S; Boccuzzi G; Henriques JPS; Spirito A; Templin C; Wilton SB; Velicki L; Correia L; Rognoni A; Ugo F; Nunez-Gil I; Fujii T; Durante A; Song X; Kawaji T; Alexopoulos D; Huczek Z; Gonzàlez Juanatey JR; Nie SP; Kawashiri MA; Morbiducci U; Dominguez-Rodriguez A; Destefanis P; Luciano A; De Ferrari GM; Varbella F; Montagna L; D'Ascenzo F; Cerrato E
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1171-1182. PubMed ID: 34224052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry.
    Xi Z; Qiu Z; Li J; Qiu H; Guo T; Wang Y; Zheng J; Gao Y; Gao R
    Platelets; 2022 Nov; 33(8):1270-1278. PubMed ID: 36050819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Net clinical benefit of different strategies of dual antiplatelet therapy in elderly patients: Data from the praise registry.
    D'Ascenzo F; Elia E; de Filippo O; Manai R; Breviario S; Bruno F; Iannaccone M; Wańha W; Bianco M; Patti G; Raposeiras-Roubin S; Abu-Assi E; Bo M; De Ferrari GM; Conrotto F;
    Int J Cardiol; 2022 Apr; 353():9-14. PubMed ID: 35090983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age- and Sex-Specific Disparities in Outcomes After Ticagrelor Versus Clopidogrel in East Asian Patients.
    Jang MH; Kim AR; Kim T; Oh HJ; Lee JH; Lee YJ; Kim S; Lee J; Kim JH; Cha SJ; Kim TO; Kang DY; Lee PH; Ahn JM; Park DW; Park SJ;
    Am J Cardiol; 2023 Nov; 207():237-244. PubMed ID: 37757520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The contribution of genotype-guided selection of P2Y
    Wu Y; Yu D; Zhang L; Wu Y; Shu B; Ma L; Shi T
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1249-1259. PubMed ID: 37449992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of ticagrelor and clopidogrel in anemic patients with acute coronary syndrome: efficacy and safety outcomes over one year.
    Onuk T; Polat F; Yaylak B; Akyüz Ş; Kolak Z; Durak F
    Eur J Clin Pharmacol; 2024 May; 80(5):759-770. PubMed ID: 38360988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry.
    Gragnano F; Moscarella E; Calabrò P; Cesaro A; Pafundi PC; Ielasi A; Patti G; Cavallari I; Antonucci E; Cirillo P; Pignatelli P; Palareti G; Pelliccia F; Gaudio C; Sasso FC; Pengo V; Gresele P; Marcucci R;
    Intern Emerg Med; 2021 Mar; 16(2):379-387. PubMed ID: 32557093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ischemic and Bleeding Outcomes of Potent P2Y12 Inhibitor Antiplatelet Agents Versus Clopidogrel in Elderly Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials.
    Abusnina W; Al-Abdouh A; Bizanti A; Gill G; Houssien A; Alshebani Y; Kanmanthareddy A; Dahal K
    Cardiovasc Revasc Med; 2022 May; 38():54-60. PubMed ID: 34384690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.